Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial

Diabetes, Obesity and Metabolism

Volumn 15, Issue 10, 2013, Pages 931-937

  Bray, G A ^a   Smith, S R ^b   Banerji, M A ^c   Tripathy, D ^d   Clement, S C ^e   Buchanan, T A ^f   Henry, R R ^g   Kitabchi, A E ^h   Mudaliar, S ^g   Musi, N ^d   Ratner, R E ⁱ   Schwenke, D C ^j,k   Stentz, F B ^h   Reaven, P D ^k   Defronzo, R A ^d  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b FLORIDA HOSPITAL   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

ⁱ MEDSTAR RESEARCH INSTITUTE   (United States)

^j ARIZONA STATE UNIVERSITY   (United States)

^k Phoenix Veterans Affairs Health Care System   (United States)

more..

Author keywords

Clinical trial; Fat; Glycaemic control

Indexed keywords

PIOGLITAZONE; PLACEBO;

ADULT; ANKLE FRACTURE; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BODY WEIGHT; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FIBULA FRACTURE; FOLLOW UP; FOOT FRACTURE; HAND FRACTURE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LEG; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PELVIS; RIB; THORACIC SPINE; TIBIA FRACTURE; TRUNK; WRIST FRACTURE;

CLINICAL TRIAL; FAT; GLYCAEMIC CONTROL;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; BODY MASS INDEX; BODY WEIGHT; BONE DENSITY; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PREDIABETIC STATE; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84883739707     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12099     Document Type: Article

References (41)

1. Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006; 29: 1263-1268.
2. World Health Organization. Diabetes programme facts and figures, 2007. World Health Organisation; Geneva, Switzerland Available from URL: http:/www.who.int/diabetes/facts/en. Accessed 5 January 2009.
3. Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial. Metabolism 2005; 54: 24-32.
4. Mori Y, Murakawa Y, Okada K et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999; 22: 908-912.
5. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-293.
6. Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-2791.
7. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2006; 366: 1279-1289.
8. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188.
9. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of Pioglitazone vs Glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE Randomized Controlled Trial. JAMA 2008; 299: 1561-1573.
10. Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572-2581.
11. Xiang AH, Hodis HN, Kawakubo M et al. Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes. Atherosclerosis 2008; 1999: 207-214.
12. De Fronzo RA, Tripathy D, Schwenke DC et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. NEJM 2011; 364: 1104-1115.
13. Xiang AH, Peters RK, Kjos SL et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006; 55: 517-522.
14. Miyazaki Y, Mahankali A, Matsuda M et al. Improved glycemic control and enhanced insulin sensitivity in liver and muscle in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24: 710-719.
15. DeFronzo RA, Banerji MA, Bray GA et al. Actos Now for the Prevention of Diabetes (ACT NOW) Study. BMC Endocr Disord 2009; 9: 17-25.
16. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. NEJM 2006; 355: 2427-2443.
17. Kahn SE, Zinman B, Lachin JM et al. Rosiglitazone associated fractures in type 2 diabetes: an analysis from ADOPT. Diabetes Care 2008; 31: 845-851.
18. Meir C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Int Med 2008; 168: 820-825.
19. Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M. Rosiglitazone and pioglitazone increases fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab 2010; 12: 716-721.
20. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Can Med Assoc J 2009; 180: 32-39.
21. Rasouli N, Raue U, Miles LM et al. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 2005; 288: E930-E934.
22. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
23. Gupta AK, Bray GA, Greenway FL, Martin CK, Johnson WD, Smith SR. Pioglitazone, but not metformin, reduces liver fat in type-2 diabetes mellitus independent of weight changes. J Diab Comp 2010; 24: 289-296.
24. Shah PK, Mudaliar S, Chang AR et al. Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 505-510.
25. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type 2 diabetic patients. Internat J Obesity 2004; 28: 783-789.
26. Bays H, Mandarino L, DeFronzo RA. Role of the adipocytes, FFA, and ectopic fat in the pathogenesis of type 2 diabetes mellitus: PPAR agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463-478.
27. Bajaj M, Baig R, Suraamornkul S et al. Effect of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 1916-1923.
28. Rebuffé-Scrive M, Brönnegard M, Nilsson A, Eldh J, Gustafsson JA, Björntorp P. Steroid hormone receptors in human adipose tissues. J Clin Endocrinol Metab 1990; 71: 1215-1219.
29. Yki-Jarvinen H. Thiazolidinediones. NEJM 2004; 351: 1106-1118.
30. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514.
31. Miyazaki Y, Glass L, Triplitt C et al. Effect of rosiglitazone on glucose and free fatty acid metabolism in type 2 diabetic patients. Diabetologia 2001; 44: 2210-2219.
32. Coletta DK, Sriwijitkamol A, Wajcberg E et al. Pioglitazone stimulates AMPK-activated protein kinase signaling and increases the expression of genes involved in adiponectin signaling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomized trial. Diabetologia 2009; 52: 723-732.
33. DeFronzo RA. Banting lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.
34. Miyazaki M, De Filippis E, Bajaj M et al. Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician. Br J Diabetes Vasc Dis 2005; 5: 28-35.
35. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Phyisol Endocrinol Metab 2007; 292: E871-E883.
36. Lu M, Sarruf DA, Talukdar S et al. Brain PPAR-y promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med 2011; 17: 618-622.
37. Lafontan M. Differential recruitment and differential regulation by physiological amines of fat cell beta-1, beta-2 and beta-3 adrenergic receptors expressed in native fat cells and in transfected cell lines. Cell Signal 1994; 6: 363-392.
38. Svendsen OL, Haarbo J, Hassager C, Christian C. Accuracy of measurements of body composition by dual-energy X-ray absorptiometry. Am J Clin Nutr 1993; 57: 605-608.
39. Evans EM, Mojtahedi MC, Kessinger RB, Misic MM. Simulated change in body fatness affects Hologic QDR 4500A whole body and central DXA bone measures. J Clin Densitom 2006; 9: 315-322.
40. Tothill P, Avenell A. Errors in dual-energy X-ray absorptiometry of the lumbar spine owing to fat distribution and soft tissue thickness during weight change. Br J Radiol 1993; 67: 71-75.
41. Tothill P, Hannan WJ, Cowen S, Freeman CP. Anomalies of changes in total-body bone mineral by dual-energy X-ray absorptiometry during weight change. J Bone Min Metab 1997; 12: 1908-1921.